Company / Accounts Receivable
Zoetis Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.6B
FY2025
5-year range
$1.1B / $1.6B
FY2021-FY2025
Trend
+20.8%
vs FY2024
Sector context
#13 of 113
Health Care
What the data says
Zoetis's accounts receivable of $1.6B is higher than 88% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 5 consecutive years, from $1.0B in FY2020 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +9.4%. Top quartile in the Health Care sector.
Improved from $1.3B to $1.6B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 113This company $1.6B Sector average $1.1B
▼
+39.8% above sector average
Key checks
Key Insights
- Zoetis's accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, accounts receivable increased 20.8% year-over-year.
- Ranks #13 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +20.8% |
| FY2024 | $1.3B | +0.9% |
| FY2023 | $1.3B | +7.3% |
| FY2022 | $1.2B | +7.2% |
| FY2021 | $1.1B | +11.8% |
| FY2020 | $1.0B | -6.7% |
| FY2019 | $1.1B | +4.8% |
| FY2018 | $1.0B | +3.8% |
| FY2017 | $998.0M | +9.3% |
| FY2016 | $913.0M | -2.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026